gastric cancer
Conditions
Interventions
Group 1:Albumin binding paclitaxel+intraperitoneal hyperthermic perfusion chemotherapy
Group 2:Solvent paclitaxel+intraperitoneal hyperthermic perfusion chemotherapy
Group 3:Intravenous and intraperitoneal infusion of solvent paclitaxel combined with oral administration of S-1
Sponsors
Liaoning Provincial Cancer Hospital/Affiliated Cancer Hospital of Dalian University of Technology
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-75 years; 2. ECOG score = 3 months; 4. Histologically confirmed as gastric adenocarcinoma, with clear peritoneal metastasis (positive cytology of laparoscopic exploration, ascites puncture/peritoneal lavage fluid exfoliation), but without digestive tract obstruction; 5. The clinical staging was CT3-4NxM1 (M1 was peritoneal metastasis); 6. Laboratory examination can tolerate surgery and chemotherapy.
Exclusion criteria
Exclusion criteria: 1. Anti tumor therapy (surgery, chemotherapy, immunization, targeted therapy, etc.) has been carried out for gastric cancer in the past, but the time to this treatment is less than half a year; 2. In addition to peritoneal metastasis, there are other distant metastasis; 3. Patients with other malignant diseases in the last 5 years, excluding cured skin cancer and cervical carcinoma in situ; 4. If there is a history of uncontrolled epilepsy, central nervous system disease or mental disorder, the doctor shall judge whether the clinical severity hinders the signing of the informed consent or affects the compliance of the patient with oral drugs; 5. Clinically serious (i.e. active) heart disease, such as symptomatic coronary heart disease, New York Heart Association (NYHA) Class II or more severe congestive heart failure or serious arrhythmia requiring drug intervention, or a history of myocardial infarction in the last 12 months; 6. Severe uncontrolled repeated infection includes abdominal infection, or other serious uncontrolled concomitant diseases; 7. Gastric cancer with complication (bleeding, perforation, obstruction) requiring emergency operation; 8. Patients with known deficiency of dihydropyrimidine dehydrogenase (DPD); 9 Patients who are allergic to paclitaxel or any of the drug ingredients of the project; 10. Pregnant or lactating patients; 11. Reproductive age patients (including men) who refuse to take contraceptive measures; 12. Extensive intra-abdominal adhesions due to various causes.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival;Overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence rate of adverse reactions;Objective response rate;Disease control rate;R0 resection rate;Quality of life; | — |
Countries
China
Contacts
Public ContactZheng Zhichao, Zhang Tao
Liaoning Provincial Cancer Hospital/Affiliated Cancer Hospital of Dalian University of Technology
Outcome results
None listed